- Home
- NPKI vs AUTL Comparison
NPKI vs AUTL Comparison
Compare NPKI & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPKI
- AUTL
- Stock Information
- Founded
- NPKI 1932
- AUTL 2014
- Country
- NPKI United States
- AUTL United Kingdom
- Employees
- NPKI N/A
- AUTL N/A
- Industry
- NPKI Metal Fabrications
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NPKI Industrials
- AUTL Health Care
- Exchange
- NPKI Nasdaq
- AUTL Nasdaq
- Market Cap
- NPKI 621.1M
- AUTL 590.8M
- IPO Year
- NPKI N/A
- AUTL 2018
- Fundamental
- Price
- NPKI $7.01
- AUTL $2.16
- Analyst Decision
- NPKI
- AUTL Strong Buy
- Analyst Count
- NPKI 0
- AUTL 3
- Target Price
- NPKI N/A
- AUTL $10.20
- AVG Volume (30 Days)
- NPKI 385.2K
- AUTL 1.1M
- Earning Date
- NPKI 02-19-2025
- AUTL 03-13-2025
- Dividend Yield
- NPKI N/A
- AUTL N/A
- EPS Growth
- NPKI N/A
- AUTL N/A
- EPS
- NPKI N/A
- AUTL N/A
- Revenue
- NPKI $748,372,000.00
- AUTL $10,091,000.00
- Revenue This Year
- NPKI N/A
- AUTL $851.83
- Revenue Next Year
- NPKI N/A
- AUTL $224.65
- P/E Ratio
- NPKI N/A
- AUTL N/A
- Revenue Growth
- NPKI 93.70
- AUTL 82.71
- 52 Week Low
- NPKI $5.61
- AUTL $2.07
- 52 Week High
- NPKI $8.65
- AUTL $7.37
- Technical
- Relative Strength Index (RSI)
- NPKI N/A
- AUTL 41.40
- Support Level
- NPKI N/A
- AUTL $2.07
- Resistance Level
- NPKI N/A
- AUTL $2.26
- Average True Range (ATR)
- NPKI 0.00
- AUTL 0.12
- MACD
- NPKI 0.00
- AUTL 0.01
- Stochastic Oscillator
- NPKI 0.00
- AUTL 25.00
About NPKI NPK International Inc. Common Stock
NPK International Inc Formerly Newpark Resources Inc is a diversified supplier providing environmentally-sensitive products, as well as rentals and services to customers across multiple industries. The company has two operating segments: Industrial Solutions and Fluids Systems. Fluids Systems segment which generates the majority of the revenue, provides drilling, completion, and stimulation fluids products and related technical services to customers for oil, natural gas, and geothermal projects. Geographically, the company derives majority of its revenue from the United States and also has its presence in Canada, EMEA, Latin America, and Asia Pacific regions.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.